Numerous studies have shown the abnormal expression of PGRN in various cancers, including gastric cancer (GC), where its overexpression is closely associated with tumor proliferation, aggressiveness and adverse prognostic outcomes (Chen S. et al., 2022; Zhao et al., 2020; Do et al., 2021; Purrahman et al., 2022). Here, GRN is linked to cancer.